WRAIR and the U.S. Army Medical Research and Development Command are playing a key role in the ongoing COVID-19 response, building upon WRAIR's ability to rapidly respond to outbreaks on an accelerated timeline for the development of diagnostics, vaccines and treatments.
WRAIR closely partners with researchers at other U.S. government agencies, and recent work on the Ebola and Zika outbreaks has helped refine these coordination efforts.
In addition to EIDB's efforts in vaccine, monoclonal antibody and epidemiology research, WRAIR is also leading efforts in COVID-19 diagnostics and drug discovery. Visit the WRAIR website for more information on the Institute's COVID-19 response.